Cargando…
Therapeutical use of probiotic formulations in clinical practice
BACKGROUND & AIMS: The spreading of gastrointestinal diseases is growing all over the world. Although for some of them an effective therapeutic approach has been found, palliation rather than cure is very frequent due to a partial knowledge of their aethiology and pathogenesis. This review, anal...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172412/ https://www.ncbi.nlm.nih.gov/pubmed/20576332 http://dx.doi.org/10.1016/j.clnu.2010.05.004 |
_version_ | 1783524252683599872 |
---|---|
author | Iannitti, T. Palmieri, B. |
author_facet | Iannitti, T. Palmieri, B. |
author_sort | Iannitti, T. |
collection | PubMed |
description | BACKGROUND & AIMS: The spreading of gastrointestinal diseases is growing all over the world. Although for some of them an effective therapeutic approach has been found, palliation rather than cure is very frequent due to a partial knowledge of their aethiology and pathogenesis. This review, analyzing the main clinical studies, aims at being a state of the art update of the use of probiotic formulations in daily practice. METHODS: In this review we include all the most significant clinical trials involving the use of probiotic formulations for the treatment of several pathologies. RESULTS: Dysbiosis has been observed in irritable bowel syndrome patients. Probiotics may exert a beneficial effect on Crohn’s disease affected patients who have shown gut microbiota antigens and altered wall permeability. Moreover some probiotic formulations seem to enhance the therapy for Helycobacter Pylori reducing its pathogenic potential. Intestinal ecology imbalance has been also linked to cancer induction, allergy, skin and urogenital diseases. In addition probiotics administration seems to be particularly useful to ease post-operative complications. CONCLUSION: Further future clinical trials, involving large numbers of patients, will be mandatory to achieve definite evidence of the preventive and curative role of probiotics in medical practice. |
format | Online Article Text |
id | pubmed-7172412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71724122020-04-22 Therapeutical use of probiotic formulations in clinical practice Iannitti, T. Palmieri, B. Clin Nutr Review BACKGROUND & AIMS: The spreading of gastrointestinal diseases is growing all over the world. Although for some of them an effective therapeutic approach has been found, palliation rather than cure is very frequent due to a partial knowledge of their aethiology and pathogenesis. This review, analyzing the main clinical studies, aims at being a state of the art update of the use of probiotic formulations in daily practice. METHODS: In this review we include all the most significant clinical trials involving the use of probiotic formulations for the treatment of several pathologies. RESULTS: Dysbiosis has been observed in irritable bowel syndrome patients. Probiotics may exert a beneficial effect on Crohn’s disease affected patients who have shown gut microbiota antigens and altered wall permeability. Moreover some probiotic formulations seem to enhance the therapy for Helycobacter Pylori reducing its pathogenic potential. Intestinal ecology imbalance has been also linked to cancer induction, allergy, skin and urogenital diseases. In addition probiotics administration seems to be particularly useful to ease post-operative complications. CONCLUSION: Further future clinical trials, involving large numbers of patients, will be mandatory to achieve definite evidence of the preventive and curative role of probiotics in medical practice. Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. 2010-12 2010-06-23 /pmc/articles/PMC7172412/ /pubmed/20576332 http://dx.doi.org/10.1016/j.clnu.2010.05.004 Text en Copyright © 2010 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Iannitti, T. Palmieri, B. Therapeutical use of probiotic formulations in clinical practice |
title | Therapeutical use of probiotic formulations in clinical practice |
title_full | Therapeutical use of probiotic formulations in clinical practice |
title_fullStr | Therapeutical use of probiotic formulations in clinical practice |
title_full_unstemmed | Therapeutical use of probiotic formulations in clinical practice |
title_short | Therapeutical use of probiotic formulations in clinical practice |
title_sort | therapeutical use of probiotic formulations in clinical practice |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172412/ https://www.ncbi.nlm.nih.gov/pubmed/20576332 http://dx.doi.org/10.1016/j.clnu.2010.05.004 |
work_keys_str_mv | AT iannittit therapeuticaluseofprobioticformulationsinclinicalpractice AT palmierib therapeuticaluseofprobioticformulationsinclinicalpractice |